Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | IGF1R | P08069 | 2/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 15/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777661 | 0.93 | SYK (0.86) | SYKIGF1RRIPK1JAK2LCK | |
| SCHEMBL1777291 | 0.93 | SYK (0.86) | SYKIGF1RRIPK1JAK2LCK | |
| SCHEMBL1777734 | 0.88 | SYK (0.79) | SYKIGF1RRIPK1JAK2LCK | |
| SCHEMBL1777104 | 0.87 | SYK (0.77) | SYKIGF1RRIPK1NPC1RAB9A | |
| SCHEMBL14427642 | 0.86 | SYK (0.76) | SYKIGF1RRIPK1NPC1RAB9A | |
| SCHEMBL1777627 | 0.86 | SYK (0.75) | SYKIGF1RRIPK1JAK2LCK | |
| SCHEMBL1776988 | 0.85 | SYK (0.74) | SYKIGF1RRIPK1JAK2LCK | |
| SCHEMBL1777444 | 0.85 | SYK (0.73) | SYKIGF1RNPC1RAB9AATM | |
| SCHEMBL1777163 | 0.85 | SYK (0.73) | SYKIGF1RNPC1RAB9AATM | |
| SCHEMBL1778154 | 0.84 | SYK (0.73) | SYKIGF1RRIPK1JAK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |